clinical trial · NCT02675829
Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers
Solid Tumor CancersLung CancerBladder CancerUrinary Tract Cancersado-trastuzumab emtansine
brief summary
The purpose of this study is to find out what effects, a drug called ado-trastuzumab emtansine has on the patient and their cancer which is thought to be controlled by the abnormal HER2 gene.
started
Feb 1, 2016
primary completion
Feb 1, 2027
completion
Feb 1, 2027
last updated
Mar 4, 2026
official title
A Phase 2 Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol